1 Min Read
March 8 (Reuters) - Aeglea Bio Therapeutics Inc:
* AEGLEA BIO THERAPEUTICS - DOSING OF FIRST UVEAL AND CUTANEOUS MELANOMA PATIENTS WITH PEGZILARGINASE IN OPEN-LABEL PHASE 1 COHORT EXPANSIONS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.